President Donald Trump has announced a new pricing agreement with pharmaceutical giant Regeneron. This marks the 17th deal his administration has reached with major pharmaceutical companies in less than a year, and it may be the most extensive one yet.
The agreement is centered on so-called Most-Favored-Nation (MFN) pricing, a policy requiring that American patients pay no more for prescription drugs than the lowest price charged to any other “developed nation.”
Regeneron is the 17th pharmaceutical giant offering to sell their drugs at Most-Favored-Nation drug pricing. 🇺🇸
It's simple: President Trump refuses to let America get ripped off in the global drug market. The United States will have the LOWEST drug prices anywhere in the world. pic.twitter.com/W3Uyh602Ao
— The White House (@WhiteHouse) April 23, 2026
According to an April 23 White House Fact Sheet, every state Medicaid program – including Texas – will gain access to MFN pricing on new Regeneron products and medications.
The White House projects the deal will generate hundreds of millions of dollars in savings for the program, which aims to serve low-income and disabled Americans.
Cholesterol Drug Price Cut in Half
Among the most immediate changes Americans may notice is a reduction in the price of Praluent, a widely prescribed cholesterol-lowering medication. Patients who purchase through TrumpRx.gov, the administration’s direct-to-patient drug discount platform launched in February, will see the price drop from $537 to $225.
TrumpRx launched earlier this year, as previously reported by The Dallas Express, as a portal where Americans can purchase medicines at MFN-aligned prices, bypassing traditional pharmacies.
Free Gene Therapy for Rare Genetic Deafness
Another standout announcement involves Otarmeni, a newly approved gene therapy developed by Regeneron to treat a rare form of genetic deafness. Under the agreement, the treatment will be provided to American patients at no cost.
Otarmeni received FDA approval through what the White House described as an “expedited review process” under the Commissioner’s National Priority Voucher (CNPV) program, a system aimed at speeding up approval of important health treatments for Americans.
Regeneron Pledges $27 Billion in U.S. Investments
Beyond pricing drops on new meds, Regeneron also committed to investing $27 billion in domestic research, development, and manufacturing through 2029. The company also pledged to more than double its U.S.-based manufacturing capacity for biologic medicines distributed across the country.
